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Effects of the Addition of
Beta2-agonist Tulobuterol Patches to
Inhaled Corticosteroid in Patients with
Asthma
Soichiro Hozawa1,2, Yoshinori Haruta3, Michikazu Terada1 and Michio Yamakido4
ABSTRACT
Background: Whether the additive effects of the tulobuterol patch (TP), the world’s first transdermal beta2-
agonist preparation, are useful in asthma patients receiving inhaled corticosteroid (ICS) is unclear. To examine
the add-on effects of TP on bronchial hyperresponsiveness and reduction of the percentage of sputum eosino-
phils, and to compare add-on effects of TP, slow-release theophylline (SRT), and a leukotriene receptor an-
tagonist (LTRA) in patients with asthma receiving ICS.
Methods: Study 1: We randomly allocated 24 patients with asthma receiving ICS alone in equal numbers to
either control treatment (ICS alone at conventional doses) or TP treatment (ICS at conventional doses plus TP
at 2 mgday). Following a 2-week observation period, patients received the allocated drug regimens for 4
weeks. Methacholine challenge test and measurement of percentage of eosinophils in hypertonic saline-
induced sputum were performed before and after the treatment period. Study 2: We compared add-on effects
of TP, SRT, and LTRA in 65 patients with asthma receiving ICS alone, using spirometry and peak expiratory
flow (PEF). Participants in these studies had experienced decrease in morning PEF to <80% of the predicted
value at least twice a week.
Results: Study 1: In the TP group, improvement of bronchial hyperresponsiveness and decrease in percent-
age of sputum eosinophils both indicated a statistically significant difference (p < 0.01, and p < 0.05, respec-
tively). These findings were not observed in the control group. Study 2: forced expiratory volume in 1 second
(FEV1) and PEF markedly increased after treatment with TP compared with treatment with SRT or LTRA.
Conclusions: These findings suggest that TP can be used as a long-term add-on controller for patients with
asthma receiving ICS.
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INTRODUCTION
Bronchial asthma is a chronic disease associated with
allergic airway inflammation, and causes airflow ob-
struction, bronchial hyperresponsiveness, and airway
remodeling as it progresses. The most important tar-
get in the long-term treatment of asthma control is al-
lergic airway inflammation, and consensus has been
reached worldwide that inhaled corticosteroids (ICS)
are useful as first-line controllers for long-term man-
agement of bronchial asthma. However, the efficacy
of ICS plateaus at high doses, and adverse reactions
to high-dose ICS can be critical.1 Many patients with
asthma do not respond well to ICS alone and experi-
ence deterioration in the respiratory function in the
morning, also known as ‘morning dip’. It has been re-
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ported that the addition of another controller to a
regimen of ICS regimen at regular doses is more
beneficial than increasing the dosage of corticoster-
oid for treating such patients.2-7 In global guidelines
for the treatment of asthma, such as those provided
by the Global Initiative for Asthma (GINA) and the
US National Institutes of Heath (NIH), long-acting in-
haled beta2-agonists, such as salmeterol, are posi-
tioned as first add-on controllers for inhaled corti-
costeroids because of their excellent improvement of
airflow obstruction.8,9 In addition, slow-release theo-
phylline preparations have attracted interest because
they exhibit anti-inflammatory as well as bronchodila-
tor effects.10,11 Leukotriene receptor antagonists have
been demonstrated to be clinically beneficial in many
countries, and have been confirmed to inhibit airway
infiltration by eosinophils.7,12
The tulobuterol patch (Abbott Japan, Tokyo, Ja-
pan), the world’s first transdermal beta2-agonist
preparation, was developed in Japan, and uses a
transdermal drug delivery system that can maintain
effective blood levels of tulobuterol for 24 hours when
applied to the skin once daily. Its adhesive layer is
stable when attached to a mildly fat-soluble and basic
surface, and serves as a drug container because its
reservoir system retains tulobuterol as crystals. With
this system, the concentration of soluble tulobuterol
in the adhesive layer is stably maintained for a long
period of time, and the patch releases tulobuterol
continuously into the skin to which it adheres.13
Since currently available oral beta2-agonists reach
peak blood concentrations within 3 hours of admini-
stration, patients with asthma who take this before
bed cannot achieve maximum bronchodilation in the
early morning. In addition, oral beta2-agonists often
cause generalized, clinically significant adverse drug
reactions such as tremor and palpitations due to
steep increases in blood drug concentration. How-
ever, the tulobuterol patch overcomes these disad-
vantages by including a special transdermal drug de-
livery system. According to guidelines for treatment
and control of asthma in Japan, the tulobuterol patch
is a useful long-acting beta2-agonist.14 Tamura et al.
have reported that the tulobuterol patch exerts dose-
related, add-on effects in patients receiving ICS.15
In the present study, to clarify the usefulness of the
tulobuterol patch as an add-on controller for patients
receiving ICS for long-term management of asthma,
we examined the add-on effects of the tulobuterol
patch in morning peak expiratory flow (PEF), bron-
chial hyperresponsiveness (BHR), and percentage of
sputum eosinophils in patients receiving ICS. In addi-
tion, we compared the add-on effects of the tu-
lobuterol patch, slow-release theophylline, and a leu-
kotriene receptor antagonist in patients receiving ICS
clinically.
METHODS
STUDY 1
The participants were adult, non-smoking patients
with stable bronchial asthma with minimal or no
symptoms who visited the Department of Allergology
of Mazda Hospital regularly, had received ICS for at
least 6 months before the study, received ICS alone
for asthma treatment (fluticasone propionate 200
μgday) without other controllers during the 4-week
period preceding the study, had experienced a de-
crease in morning PEF to <80% predicted value at
least twice a week, and for whom treatment with
short-acting inhaled beta2-agonists had improved
morning PEF by15%. Patients who had undergone
systemic administration of corticosteroids during the
preceding 4-week period, had signssymptoms of vi-
ral infection during this study, and those with condi-
tions such as COPD, possibly hindering evaluation of
drug treatment, were excluded.
Using the envelope method, eligible patients, who
were matched by dose of ICS (fluticasone propionate
at 200 μgday, 400 μgday, or 800 μgday), were ran-
domly allocated to either control treatment (with ICS
at conventional doses) or tulobuterol patch treatment
(ICS at conventional doses plus tulobuterol patch at 2
mgday in the evening) for each ICS dose. The enve-
lopes were opened by an independent pharmacist in-
volved in neither the diagnosis nor treatment of the
patients evaluated. Table 1 shows the characteristics
of the enrolled patients. Although treatment with 800
μgday of fluticasone propionate alone appeared to be
non-standard, in patients who exhibited a good
course with treatment with 800 μgday of fluticasone
propionate and another controller and who wished to
discontinue the combined controller, treatment with
800 μgday of fluticasone propionate alone was se-
lected.
Following a 2-week observation period, patients re-
ceived the allocated drug regimens for 4 weeks, and
underwent PEF monitoring during the observation
and treatment periods to evaluate changes in morn-
ing PEF. Methacholine challenge testing, measure-
ment of percentage sputum eosinophils, and spirome-
try were performed before the treatment period and
after a 2-day washout period following the treatment
period. PEF was measured using a mini-Wright peak
flow meter (Clemente Clarke International Ltd., Har-
low, Essex, UK). PEF was predicted using Tsukioka’s
equation, and percentage of measured to predicted
PEF (% PEF) was calculated.16 Bronchial responsive-
ness was evaluated by methacholine challenge.17
Methacholine chloride (Sigma Chemical Co., St.
Louis, MO, USA) was dissolved in physiological sa-
line to obtain two-fold-increasing concentrations (0.04
to 20 mgmL). Saline or methacholine solution was
inhaled from a Devilbiss 646 Nebulizer (Devilbiss
Co., Somerset, PA, USA) at 5 Lminute. Nebulizer
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Table 1 Characteristics of patients in the study 1
No.
Characteristic
Control groupTulobuterol patch group
1212No.
4/84/8Sex, male/female
(24-70)50.2 ± 4.4†(29-71)48.7 ± 4.5†Age (years)
(75-130)95 ± 4.4†(74-130)100 ± 2.7†FVC, % predicted value
(65-107)84 ± 4.4†(66-100)85 ± 2.5†FEV1, % predicted value 
(68-85)75 ± 1.7†(64-86)73 ± 0.7†FEV1/FVC (%)
9/38/4Type, extrinsic/intrinsic
0/4/4/40/4/4/4Severity, Step 1/2/3/4
4/4/44/4/4Inhaled corticosteroid, FP 200/400/800 (μg/day) 
† Mean ± SE (range). FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; FP, fluticasone propionate.
output was 0.28 mL2 minute. After a 2-minute inhala-
tion of saline or methacholine solution by tidal
breathing wearing a nose clip, spirometry was per-
formed (Chestac-11; Chest MI, Tokyo, Japan). After
changes in forced expiratory volume in 1 second
(FEV1) following saline inhalation were confirmed to
be below 10%, two-fold-increasing concentrations of
methacholine solution were successively adminis-
tered until a decrease of 20% or more in FEV1. Values
were semi-logarithmically plotted, and the meth-
acholine concentration producing 20% decrease in
FEV1 (PC20-FEV1) was calculated as an index of
bronchial hyperresponsiveness (BHR). Sputum speci-
mens to determine percentage sputum eosinophils
were induced by inhalation of increasing concentra-
tions of hypertonic saline (0.9, 1.8, 3, 4, and 5%), and
patients were encouraged to cough deeply after each
inhalation. Cell plugs in sputum were separated from
saliva and Wright-Giemsastained to count inflamma-
tory cells. Eosinophil percentages were determined
by counting 900 cells by light-microscopy.18
Written informed consent was obtained from all pa-
tients after explanation of the study’s purpose. The
study protocol was approved by the Mazda Hospital
Ethics Committee.
Methacholine PC20-FEV1 values are presented as
geometric means with the geometric standard error
of the mean (GSEM) expressed as a factor, while
baseline FVC and FEV1 values are presented as arith-
metic means with standard errors of the mean
(SEM). Values of %PEF and percentages of eosino-
phils are presented as arithmetical means with SEM.
Categorical data were examined by the chi-square
test or Mann-Whitney U-test. Wilcoxon’s signed-rank
sum test was used for bronchial responsiveness, per-
centage sputum eosinophils, spirometry findings, and
morning PEF. p values of <0.05 (two-tailed) were con-
sidered to indicate a statistically significant differ-
ence.
STUDY 2
The participants in this study were adult, non-
smoking patients with stable bronchial asthma who
visited the Department of Allergology of Mazda Hos-
pital regularly, who had received inhaled corticoster-
oids for at least 6 months before the study, who were
receiving inhaled glucocorticosteroid alone for treat-
ment of asthma (fluticasone propionate at 200 μg
day or beclomethasone dipropionate at 200 μg
day) without other controllers during the 4-week pe-
riod preceding the study, and who had experienced a
decrease in morning peak expiratory flow (PEF) to
<80% of the expected value at least twice a week.
Since no criteria for asthmatic signssymptoms other
than PEF were included, many patients in Study 2
were nearly completely asymptomatic. Patients who
had received systemic administration of corticoster-
oids during that period, who exhibited signssymp-
toms of viral infection during the preceding 4-week
period, or who had conditions such as COPD which
might hinder evaluation of the efficacy of drug treat-
ment were excluded from the study.
Eligible patients were randomly allocated to the fol-
lowing 4 groups using the envelope method: a control
group (inhaled corticosteroids at conventional doses
alone), a pranlukast group (inhaled corticosteroids at
conventional doses plus the leukotriene receptor an-
tagonist pranlukast at 450 mgday, divided into 2
doses, morning and evening), a slow-release theo-
phylline group (inhaled corticosteroids at conven-
tional doses plus the slow-release theophylline agent
UniphylⓇ at 400 mgday in the evening), or a tu-
lobuterol patch group (inhaled corticosteroids at con-
ventional doses plus a tulobuterol patch at 2 mgday
in the evening). The envelopes were opened by an in-
dependent pharmacist involved in neither the diagno-
sis nor the treatment of the patients evaluated. Table
2 shows the clinical characteristics of the patients en-
rolled in the study.
Following the 2-week observation period, the pa-
tients received the allocated drug regimens for 4
weeks, and underwent spirometry before and after
the 4-week treatment period to evaluate changes in
morning PEF. PEF was measured using a Mini-
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Table 2 Characteristics of patients evaluated in the study 2
Group TGroup UGroup PGroup CFactor
0001-19Age (years)
101120-29
431130-39
335440-49
467450-59
131360-69
412170-
11/6 5/1112/5 10/5 Sex, female/male
 5/126/10 5/124/11Type, intrinsic/extrinsic
6545-5 Duration (years)
66546-10
135511-20
323121-30
100031-40
000041-50
  Inhaled corticosteroids 
2333BDP 200-400 μg/day
2421BDP 400-800 μg/day
0111BDP≥800 μg/day
5036FP 200-400 μg/day
5463FP 400-800 μg/day
3421FP≥800 μg/day
Abbreviations: Group C, control group; Group P, pranlukast group; Group U, slow-release theophyline group; Group T, tulobuterol 
tape group; BDP, beclomethasone dipropionate; FP, fluticasone propionate.
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Fig. 1 Changes in % predicted value of morning peak ex-
piratory flow (PEF) before to during the four-week treatment 
period in the tulobuterol patch and control groups. Values 
are presented as means and standard erors of the mean 
(SEM). **p < 0.01 vs (Pre 2 and Pre1)/2.
Wright peak flow meter (Clemente Clarke Interna-
tional Ltd., Harlow, Essex, UK). PEF was predicted
using Tsukioka’s equation, and the ratio of percent-
age measured to predicted PEF (%PEF) was calcu-
lated.16
Written informed consent was obtained from all pa-
tients who participated in this study after explanation
of the purpose of the study. The study protocol was
approved by the Ethics Committee of Mazda Hospi-
tal.
For statistical analysis, categorical patient charac-
teristics were examined using the chi-square test.
Within- and between-group comparisons of pulmo-
nary function test results were performed using Wil-
coxon’s signed-rank sum test and the Mann-Whitney
U test, respectively. P values of less than 0.05 (two-
tailed) were considered to indicate a statistically sig-
nificant difference.
RESULTS
STUDY 1
Clinical characteristics and conditions noted during
the observation period for the 24 patients subject to
analysis are shown in Table 1. There were no signifi-
cant (p < 0.05) biases in the distribution of patients
among groups for any background factor.
Mean %PEF in the tulobuterol patch group was
72.5 ± 2.2% during the observation period, 80.0 ± 1.8%
at week 1 of treatment, 80.5 ± 2.2% at week 2 of treat-
ment, 81.4 ± 2.4% at week 3 of treatment, and 82.9 ±
1.9% at week 4 of treatment. The %PEF thus improved
Add-on Effects of Tulobuterol Patch to Corticosteroids
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Fig. 2 Bronchial responsiveness to methacholine before and after four-
week treatment in the tulobuterol patch and control groups. Group values 
are presented as geometric means and geometric standard erors of the 
mean (SEM). PC20-FEV1 indicates provocative concentration of methacho-
line producing a 20% fal in FEV1. NS indicates not significant. **p < 0.01.
Table 3 FVC and FEV1 at methacholine chalenge testing before and after treatment for 4 weeks in the tulobuterol patch 
and control groups†
Control group (n = 12)Tulobuterol patch group (n = 12)
AfterBeforeAfterBefore
2.72 ± 0.192.80 ± 0.212.87 ± 0.182.96 ± 0.14FVC (L)
 93 ± 4.7 95 ± 4.4 97 ± 4.8100 ± 2.7 FVC (% pred)
2.05 ± 0.192.12 ± 0.192.17 ± 0.162.19 ± 0.12FEV1 (L)
 81 ± 5.0 84 ± 4.4 85 ± 3.3 85 ± 2.5FEV (% pred)
 74 ± 2.0 75 ± 1.7 76 ± 2.0 73 ± 0.7FEV1/FVC (%)
† Values are the mean ± SEM.
Spirometry were performed before the treatment period and after a two-day washout period folowing the treatment period.
significantly from week 1 to week 4 of treatment
(p < 0.01) (Fig. 1).
Bronchial responsiveness, as measured by meth-
acholine PC20-FEV1, was 0.35 (GSEM, 1.24) mgmL
before treatment and 0.51 (GSEM, 1.22) mgmL after
treatment with the tulobuterol patch, with a signifi-
cant improvement observed after treatment (p < 0.01)
(Fig. 2). FEV1 and FVC at the time of methacholine
challenge testing exhibited no changes from baseline
values (Table 3). Percentage of sputum eosinophils
decreased significantly from 12.7 ± 1.8% before treat-
ment to 8.7 ± 0.9% after treatment (p < 0.05) (Fig. 3).
The patients in the control group exhibited no
changes over time in %PEF, PC20-FEV1, or percent-
age of eosinophils (Fig. 1―3). None of the 12 patients
in the tulobuterol patch group experienced systemic
adverse drug reactions such as tremor or palpita-
tions.
STUDY 2
Table 2 shows the clinical characteristics and condi-
tions during the observation period for the 65 pa-
tients. There were no significant biases in the distri-
bution of patients among groups for any background
factor.
Spirometry findings improved after treatment with
the tulobuterol patch compared with the baseline: in
the tulobuterol patch group, FEV1 increased from
2.08 ± 0.15 L to 2.25 ± 0.17 L (p < 0.05) and peak expi-
ratory flow rate (PEFR) from 6.05 ± 0.45 Ls to 6.52 ±
Hozawa S et al.
514 Allergology International Vol 58, No4, 2009 www.jsaweb.jp
30
20
10
0
Before After Before After
Tulobuterol patch group
(n = 12)
Control group
(n = 12)
S
pu
tu
m
 e
os
in
op
hi
ls
 (
%
)
* NS
Fig. 3 Percentages of sputum eosinophils before and after treatment for 
4 weeks in the tulobuterol patch and control groups. Group values are 
means and standard erors of the mean. NS indicates not significant. 
*p < 0.05.
0.45 Ls (p < 0.05). No significant improvement in spi-
rometry findings was observed in the pranlukast,
slow-release theophylline, or control group (Table 4).
Baseline morning PEF values were 404.5 ± 26.7,
356.1 ± 20.8, 360.1 ± 25.9, and 372.5 ± 27.1 Lminute
in the control, pranlukast, slow-release theophylline,
and tulobuterol groups, respectively. Morning PEFs
in the corresponding groups were 404. 2 ± 27.1, 377.5
± 28.5, 386.2 ± 28.4, and 406.5 ± 29.2 Lminute in
week 1 of treatment; 400.7 ± 27.9, 379.6 ± 28.0, 385.8 ±
28.4, and 405.5 ± 30.5 Lminute in week 2 of treat-
ment; 405.0 ± 25.7, 378.5 ± 27.4, 378.4 ± 27.6, and
406.4 ± 31.3 Lminute in week 3 of treatment; and
394.1 ± 25.5, 378.7 ± 27.8, 383.1 ± 28.0, and 411.2 ±
31.1 Lminute in week 4. Change in morning PEF
from that during the 2-week observation period was
significant in all 3 add-on groups from weeks 1 to 4 of
treatment (Fig. 4). There were no significant differ-
ences in morning PEF values among the 3 add-on
groups. On the other hand, the difference in %PEF
from baseline to week 4 of treatment (∆%PEF) was
＋5% in 1 of the 15 patients in the control group, 8 of
the 17 patients in the pranlukast group, 7 of the 16 pa-
tients in the slow-release theophylline group, and 13
of the 17 patients in the tulobuterol patch group (Fig.
5). A significant difference in %PEF was observed be-
tween the tulobuterol patch and control groups (p <
0.05). There were no significant differences in this pa-
rameter between the other add-on groups and the
control group. None of the 65 patients included in the
present study experienced adverse drug reactions
during the observation or treatment period.
DISCUSSION
We set out to determine whether the tulobuterol
patch, the world’s first transdermal beta2-agonist
preparation, which is considered a useful controller
of bronchial asthma in Japan,14,15 is usefuls as an add-
on controller for patients receiving inhaled corti-
costeroid for long-term management of asthma cases,
who had experienced decrease in morning PEF to
<80% of the predicted value at least twice a week. The
primary endpoint for Study 1 was bronchial hyperre-
sponsiveness (methacholine PC20-FEV1), while that
for Study 2 was PEF.
In Study 1, patients for whom the tulobuterol patch
was added to a regimen of inhaled corticosteroid ex-
hibited an increase in morning PEF, an improvement
in bronchial hyperresponsiveness, and a decrease in
percentage of sputum eosinophils. These findings
suggest that the addition of the tulobuterol patch may
have beneficial effects in the treatment of asthma,
such as improvementdisappearance of the morning
dip as well as improvement of bronchial hyperrespon-
siveness and allergic airway inflammation.
Since bronchial responsiveness was evaluated be-
fore the treatment period and after a 2-day wash-out
period following the treatment period, and FEV1 and
FVC values obtained on the day of methacholine chal-
lenge testing did not differ from baseline values, it ap-
Add-on Effects of Tulobuterol Patch to Corticosteroids
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Table 4 Efects on spirometry findings of addition of pranlukast, slow-release theophyline or tulobuterol patch to a regimen of 
inhaled corticosteroids
Pafter additionbefore additionGroup C (n = 15)
NS2.78 ± 0.152.84 ± 0.17FVC (L)
NS94.0 ± 4.2495.6 ± 3.77FVC (%Pred)
NS2.10 ± 0.152.15 ± 0.15FEV1 (L)
NS83.0 ± 4.8884.6 ± 4.23FEV1/FVC (%)
NS74.8 ± 1.8175.2 ± 1.6 FEV1 (%Pred)
NS5.83 ± 0.506.31 ± 0.50PEFR (L/sec)
Pafter additionbefore additionGroup U (n=16)
NS3.18 ± 0.203.10 ± 0.19FVC (L)
NS97.7 ± 3.3495.7 ± 3.91FVC (%Pred)
NS2.23 ± 0.172.19 ± 0.17FEV1 (L)
NS79.0 ± 3.5478.1 ± 4.50FEV1/FVC (%)
NS69.9 ± 2.3970.1 ± 2.20FEV1 (%Pred)
NS6.09 ± 0.505.81 ± 0.52PEFR (L/sec)
Pafter additionbefore additionGroup P (n=17)
NS2.77 ± 0.162.76 ± 0.16FVC (L)
NS95.6 ± 2.1995.2 ± 2.12FVC (%Pred)
NS2.11 ± 0.142.32 ± 0.33FEV1 (L)
NS85.2 ± 2.9383.1 ± 2.78FEV1/FVC (%)
NS75.9 ± 2.2274.5 ± 2.27FEV1 (%Pred)
NS5.77 ± 0.445.48 ± 0.46PEFR (L/sec)
Pafter additionbefore additionGroup T (n=17)
NS2.92 ± 0.172.83 ± 0.16FVC (L)
NS99.0 ± 3.6196.4 ± 3.67FVC (%Pred)
P<0.052.25 ± 0.172.08 ± 0.15FEV1 (L)
NS85.3 ± 3.0881.4 ± 3.33FEV1/FVC (%)
NS74.1 ± 2.0172.5 ± 1.88FEV1 (%Pred)
P<0.056.52 ± 0.456.05 ± 0.43PEFR (L/sec)
Abbreviations: Group C, control group; Group P, pranlukast group; Group U, slow-release theophyline group; Group T, tulobuterol 
patch group; FVC, forced vital capacity; FVC%, ratio of measured to expected FVC; FEV1, forced expiratory volume in 1 second; %FEV1, 
ratio of measured to expected FEV1; PEFR, peak expiratory flow rate.
peared that the measured values of bronchial respon-
siveness in the patients in the tulobuterol patch group
were not influenced by the direct bronchodilatory ef-
fects of tulobuterol. The improvement of bronchial
hyperresponsiveness observed in the patients in the
tulobuterol patch group thus appeared to be due
largely to improvement of airway inflammation, al-
though no significant correlation was found between
PC20 and sputum eosinophil percentage.
Reasons for this may include the fact that bronchial
hyperresponsiveness is associated with other factors
in addition to eosinophilic inflammation, and that only
a small number of cases were included in this study.
This conclusion is based on the following possible
mechanisms of interaction between inhaled corti-
costeroid and the tulobuterol patch.
First, distribution of inhaled corticosteroid into the
airway may be enhanced by the stable and prolonged
bronchodilation induced by tulobuterol patch. In a re-
cent study using impulse oscillometry (IOS), use of
the tulobuterol patch as an add-on controller im-
proved IOS indices of peripheral airway function such
as R5-R20 (small airway component) and X5 (distal
capacity reactance) in patients with asthma receiving
ICS.19 This finding indicates that tulobuterol patch
exhibits a bronchodilator effect that covers the pe-
ripheral airways to ensure sufficient distribution of
ICS not only to the central but also the peripheral air-
ways, enabling exertion of the full effects of ICS.
Secondly, interactions between corticosteroids and
beta2-agonists may play a role in improving bronchial
responsiveness.20-22 Corticosteroids diffuse from the
surface of the cell membrane into cytoplasm, where
they bind to corticosteroid receptors (CRs). CRs acti-
vated by this binding translocate into the nucleus
where they bind corticosteroid-responsive elements
and activate the transcription of genes regulated by
these elements, and inhibit the activity of transcrip-
tion factors involved in the expression of genes for
proinflammatory cytokines such as activating protein-
Hozawa S et al.
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Fig. 4 Efects of addition of pranlukast, slow-release theophyline, and tulobuterol patch 
to a regimen of inhaled corticosteroid on diference in morning PEF before to after treat-
ment (PEF). Abbreviations: Group C, control group; Group P, pranlukast group; Group U, 
slow-release theophyline group; Group T, tulobuterol patch group. *p < 0.05, **p < 0.01, 
***p < 0.001 vs Group C.
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Fig. 5 Efects of addition of pranlukast, slow-release theo-
phyline, or tulobuterol patch to a regimen of inhaled corticos-
teroid on diference in morning %PEF before to after 
treatment (Δ%PEF). Abbreviations: Group C, control group; 
Group P, pranlukast group; Group U, slow-release theophyl-
line group; Group T, tulobuterol patch group.
1 (AP-1) and nuclear factor κB (NF-κB). In addition,
CS-CR complexes bind transcription factors directly
and inhibit the transcription of proinflammatory cy-
tokine genes. Corticosteroids increase the number of
beta2-receptors and inhibit down-regulation of beta2-
receptors. On the other hand, beta2-agonists produce
bronchodilation and prime and activate CRs, thus en-
hancing the anti-asthmatic effects of corticosteroids.
Maintenance of effective blood tulobuterol concentra-
tion for 24 hours through once-daily application of tu-
lobuterol patches is important for ensuring clinically
significant add-on effects of tulobuterol for inhaled
corticosteroids, given the types of interactions that
occur between these two drugs.
Thirdly, tulobuterol has been found to significantly
inhibit the adhesion of eosinophils to endothelial cells
at clinically relevant blood concentrations in vitro.23
Since the transdermal preparation delivers tu-
lobuterol into the systemic circulation, the effects of
tulobuterol on endothelial cells appeared to contrib-
ute to the significant decrease in the percentage of
sputum eosinophils observed in patients of the tu-
lobuterol patch group.
Of the 3 possible mechanisms described above, the
first 2 appear to be related to the effects of adding in-
haled beta2-agonists to inhaled corticosteroid, while
the third appears unrelated to topical administration
of beta2-agonists. Moreover, it has been reported that
allergic airway inflammation may be masked by com-
bined treatment with inhaled corticosteroid and sal-
meterol.24,25 It has also been suggested that inhaled
beta2-agonists may accumulate in airway tissues with
allergic inflammation, and may shift the Th1Th2 bal-
ance toward a Th2-dominant pattern that results in
exacerbation of allergic airway inflammation.26 This
risk associated with inhaled beta2-agonists can be
prevented with transdermal administration of beta2-
agonists. These considerations strongly suggest the
effectiveness of adding tulobuterol patch to inhaled
Add-on Effects of Tulobuterol Patch to Corticosteroids
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corticosteroid regimens. Study 2 demonstrated that
tulobuterol patches have benefits equivalent or supe-
rior to those of slow-release theophylline and leukot-
riene receptor antagonist as an add-on controller for
patients undergoing long-term management of
asthma using ICS. Thus our findings support the po-
sitioning of the tulobuterol patch in the guidelines for
management and treatment of asthma in Japan.14
Kume et al. reported that the effects of tulobuterol
patches were not attenuated at clinically relevant
doses, and that patients treated with tulobuterol
patches and ICS did not develop resistance to treat-
ment.27 Their findings support the appropriateness of
adding tulobuterol patches as a long-term add-on con-
troller to an ICS. However, whether tulobuterol
patches can be positioned similarly to long-acting in-
haled beta2-agonists is still unclear, as are the differ-
ences in efficacy and safety between inhaled and
transdermal beta2-agonists. Animal and human clini-
cal studies comparing transdermal and inhaled prepa-
rations of beta2-agonists in terms of clinical benefits
and effects on beta2-receptors, including developing
resistance, are needed before definitive conclusions
can be drawn regarding the positioning of tulobuterol
patch in the treatment of asthma.
Our findings suggest that the addition of tu-
lobuterol patches to ICS has beneficial effects in the
treatment of asthma, including disappearance of
morning dip as well as improvement of bronchial hy-
perresponsiveness and allergic airway inflammation,
and that tulobuterol patches can be used as a long-
term add-on controller for patients with asthma re-
ceiving ICS.
ACKNOWLEDGEMENTS
The authors thank Ms. Shoko Taniguchi, pharmacist
of Mazda Hospital, for opening envelopes for random
allocation of eligible patients in Study 1 and 2.
REFERENCES
1. Matz J, Emmett A, Rickard K, Kalberg C. Addition of sal-
meterol to low-dose fluticasone versus higher-dose flutica-
sone: an analysis of asthma exacerbations. J Allergy Clin
Immunol 2001;107:783-9.
2. Greening AP, Ind PW, Northfield M, Shaw G. Added sal-
meterol versus higher-dose corticosteroid in asthma pa-
tients with symptoms on existing inhaled corticosteroid.
Lancet 1994;344:219-24.
3. Woolcock A, Lundback B, Ringdal N, Jacques LA. Com-
parison of addition of salmeterol to inhaled steroids with
doubling of the dose of inhaled steroids. Am J Respir Crit
Care Med 1996;153:1481-8.
4. Pauwels RA, Löfdahl CG, Postma DS et al. Effect of in-
haled formoterol and budesonide on exacerbations of
asthma. N Engl J Med 1997;337:1405-11.
5. Ukena D, Harnest U, Sakalauskas R et al. Comparison of
addition of theophylline to inhaled steroid with doubling
of the dose of inhaled steroid in asthma. Eur Respir J
1997;10:2754-60.
6. Evans DJ, Taylor DA, Zetterstrom O, Chung KF, O’Con-
nor BJ, Barnes PJ. A comparison of low-dose inhaled
budesonide plus theophylline and high-dose inhaled
budesonide for moderate asthma. N Engl J Med 1997;
337:1412-8.
7. Drazen JM, Israel E, O’Byrne PM. Treatment of asthma
with drugs modifying the leukotriene pathway. N Engl J
Med 1999;340:197-206.
8. National Heart, Lung, and Blood Institute. Global Initia-
tive for Asthma (GINA). Global Strategy for Asthma Man-
agement and Prevention. Revised 2006. Available from: ht
tp:www.ginasthma.org.
9. National Heart, Lung, and Blood Institute. National
Asthma Education and Prevention Program(NAEPP), Ex-
pert Panel Report 2: Guidelines for the Diagnosis and Man-
agement of Asthma. Bethesda, MD: National Institutes of
Health, 1997; NIH Publication No. 97-4051.
10. Barnes PJ, Pauwels RA. Theophylline in the management
of asthma: time for reappraisal? Eur Respir J 1994;7:579-
91.
11. Sullivan P, Bekir S, Jaffar Z, Page C, Jeffery P, Costello J.
Anti-inflammatory effects of low-dose oral theophylline in
atopic asthma. Lancet 1994;343:1006-8.
12. Bjermer L, Bisgaard H, Bousquet J et al. Montelukast and
fluticasone compared with salmeterol and fluticasone in
protecting against asthma exacerbation in adults: one
year, double-blind, randomised, comparative trial. BMJ
2003;327:891.
13. Uematsu T, Nakano M, Kosuge K, Kanamaru M, Naka-
shima M. The pharmacokinetics of the beta 2-
adrenoceptor agonist, tulobuterol, given transdermally
and by inhalation. Eur J Clin Pharmacol 1993;44:361-4.
14. Asthma Guideline Committee of the Japanese Society of
Allergology. [Asthma Prevention and Management Guide-
line 2006, Japan]. Tokyo: Kyowa Kikaku, 2006(in Japa-
nese).
15. Tamura G, Miyamoto T, Nakashima O et al. Effect of
transdermal tulobuterol added to inhaled corticosteroids
in asthma patients. Allergol Int 2005;54:615-20.
16. Tsukioka K. [Peak Expiratory Flow in Normal, Healthy
Japanese Subjects]. Revised ed. Tokyo: Kyowa Kikaku
Tsushin, 2002(in Japanese).
17. Hozawa S, Haruta Y, Ishioka S, Yamakido M. Effects of a
PAF antagonist, Y-24180, on bronchial hyperresponsive-
ness in patients with asthma. Am J Respir Crit Care Med
1995;152:1198-202.
18. Pin I, Gibson PG, Kolendowicz R et al. Use of induced
sputum cell counts to investigate airway inflammation in
asthma. Thorax 1992;47:25-9.
19. Hozawa S, Tanaka H, Terada M et al. Tulobuterol patch,
transdermal LABA, improves small airways resistance in
elderly asthma treated with inhaled corticosteroids. Am J
Respir Crit Care Med 2008;177:A611.
20. Eickelberg O, Roth M, Lörx R et al. Ligand-independent
activation of the glucocorticoid receptor by beta2-
adrenergic receptor agonists in primary human lung fi-
broblasts and vascular smooth muscle cells. J Biol Chem
1999;274:1005-10.
21. Adcock IM, Stevens DA. Molecular interactions between
corticosteroids and beta2-agonists. In: Kummer F (ed).
Treatment of Asthma: The Long-Acting Beta2-Agonists.
New York: Springer Med Wein, 1998;15-40.
22. Barnes PJ. Scientific rationale for inhaled combination
therapy with long-acting beta2-agonists and corticoster-
oids. Eur Respir J 2002;19:182-91.
23. Yamaguchi T, Nagata M, Miyazawa H, Kikuchi I, Hagi-
wara K, Kanazawa M. Tulobuterol, a β2-agonist, attenu-
Hozawa S et al.
518 Allergology International Vol 58, No4, 2009 www.jsaweb.jp
ates eosinophil adhesion to endothelial cells. Allergol Int
2005;54:283-8.
24. Mcivor RA, Pizzichini E, Turner MO, Hussack P, Har-
greave FE, Sears MR. Potential masking effects of sal-
meterol on airway inflammation in asthma. Am J Respir
Crit Care Med 1998;158:924-30.
25. Currie GP, Lee DK, Haggart K, Bates CE, Lipworth BJ.
Effects of montelukast on surrogate inflammatory mark-
ers in corticosteroid-treated patients with asthma. Am J
Respir Crit Care Med 2003;167:1232-8.
26. Panina-Bordignon P, Mazzeo D, Lucia PD et al. Beta2-
agonists prevent Th1 development by selective inhibition
of interleukin 12. J Clin Invest 1997;100:1513-9.
27. Kume H, Kondo M, Ito Y, Suzuki R, Yamaki K, Takagi K.
Effects of sustained-release tulobuterol on asthma control
and beta-adrenoceptor function. Clin Exp Pharmacol
Physiol 2002;29:1076-83.
